Idicitinib Monotherapy for Low-Risk GVHD

Ruxolitinib is a JAC-1-2 inhibitor approved by the FDA for the treatment of steroid refractory acute GVHD. It works by inhibiting the JAC-STAT pathway to prevent activation of effector donor T-cells that damage GVHD target organs. Idicitinib, unlike RuxolitinIB, has not been associated with hematologic toxicities. In a recent Phase III trial in combination with systemic corticosteroids as primary treatment of GVHD, IdicitInib showed a favorable safety profile.